Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Shares Shorted: Short Interest Up 47.4% in October

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS – Get Free Report) was the target of a large growth in short interest in October. As of October 30th, there was short interest totaling 4,556,267 shares, a growth of 47.4% from the October 15th total of 3,090,758 shares. Based on an average daily trading volume, of 6,864,487 shares, the short-interest ratio is presently 0.7 days. Currently, 7.0% of the shares of the company are sold short.

Analyst Ratings Changes

A number of brokerages have recently issued reports on ABOS. Wall Street Zen lowered shares of Acumen Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, October 17th. Lucid Cap Mkts downgraded Acumen Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 2nd. Bank of America lowered Acumen Pharmaceuticals from a “buy” rating to an “underperform” rating and set a $1.00 price objective for the company. in a report on Monday, November 2nd. Citigroup cut shares of Acumen Pharmaceuticals from a “buy” rating to a “hold” rating and set a $1.00 price objective on the stock. in a research report on Friday, October 30th. Finally, BTIG Research lowered their target price on shares of Acumen Pharmaceuticals to $1.00 and set a “buy” rating on the stock in a research note on Monday, November 2nd. One investment analyst has rated the stock with a Buy rating, three have assigned a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Reduce” and a consensus target price of $1.00.

Get Our Latest Stock Analysis on ABOS

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. ADAR1 Capital Management LLC purchased a new position in shares of Acumen Pharmaceuticals in the second quarter worth $5,637,000. BlackRock Inc. bought a new position in shares of Acumen Pharmaceuticals during the second quarter valued at $6,649,000. Bank of America Corp DE bought a new position in shares of Acumen Pharmaceuticals during the second quarter valued at $734,000. Spark Investment Management LLC purchased a new stake in shares of Acumen Pharmaceuticals during the second quarter valued at $39,000. Finally, Two Sigma Securities LLC purchased a new stake in shares of Acumen Pharmaceuticals during the second quarter valued at $32,000. 71.01% of the stock is owned by hedge funds and other institutional investors.

Acumen Pharmaceuticals Trading Down 14.0%

Acumen Pharmaceuticals stock traded down $0.03 during trading hours on Wednesday, reaching $0.20. The stock had a trading volume of 2,106,508 shares, compared to its average volume of 1,187,201. Acumen Pharmaceuticals has a 52 week low of $0.19 and a 52 week high of $3.60. The stock has a market cap of $14.32 million, a PE ratio of -0.13 and a beta of 0.51. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.89 and a quick ratio of 1.89. The company has a fifty day simple moving average of $1.73 and a 200-day simple moving average of $2.38.

Acumen Pharmaceuticals (NASDAQ:ABOS – Get Free Report) last issued its quarterly earnings data on Monday, October 26th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.04. Analysts forecast that Acumen Pharmaceuticals will post -1.50 EPS for the current fiscal year.

About Acumen Pharmaceuticals

(Get Free Report)

Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing treatments for Alzheimer’s disease. Its research focuses on soluble amyloid beta oligomers, forms of the protein that the company believes contribute to the disease. The company’s lead investigational product, sabirnetug (ACU193), is a monoclonal antibody designed to selectively target amyloid beta oligomers. Acumen has evaluated the treatment in clinical studies of people with early Alzheimer’s disease; it is investigational and has not been approved for commercial use.

Featured Stories

Receive News & Ratings for Acumen Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acumen Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.